載入...
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
BACKGROUND: Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was cardioprotective in this population. The objecti...
Na minha lista:
| 發表在: | Orphanet J Rare Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5319045/ https://ncbi.nlm.nih.gov/pubmed/28219442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0590-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|